DOACs and Drug Interactions in Transplant Patients – JTH
Journal of Thrombosis and Haemostasis shared a post on LinkedIn about a recent article by Andreas Verstraete et al., adding:
“Direct oral anticoagulant use and drug-drug interactions in transplant recipients receiving calcineurin inhibitors.
Cyclosporine and tacrolimus inhibit the CYP3A4 and P-glycoprotein pathways that clear DOACs, raising concern about elevated drug levels.
Among 216 transplant recipients with 360 DOAC measurements, 11% were above-range, more often with rivaroxaban (20%) and apixaban (18%) than edoxaban (4%).
Higher levels tracked with strong CYP3A4 or P-glycoprotein inhibitors, lower weight, reduced kidney function, and cyclosporine use.”
Title: Direct oral anticoagulant use and drug-drug interactions in transplant recipients receiving calcineurin inhibitors
Authors: Andreas Verstraete, Erwin Dreesen, Quentin Van Thillo, Margot Erard, Dirk R.J. Kuypers, Marc Jacquemin, Filip Rega, Johan Van Cleemput, Jef Verbeek, Robin Vos, Peter Verhamme, Lorenz Van der Linden, Thomas Vanassche
Other posts about Journal of Thrombosis and Haemostasis on Hemostasis Today.
-
Aug 23, 2026, 17:51Gurpreet Kaurr: A Proud Milestone in Haematology and Oncology
-
Aug 23, 2026, 17:33Kathrine Kaspersen: How Voluntary Plasma Donors Helped Transform Denmark’s Plasma Supply
-
Aug 23, 2026, 16:51Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:50Lale Tokgözoğlu: New PCSK9i Research Published in the European Heart Journal
-
Aug 23, 2026, 16:44Eric Gehrie: Your 2026 Guide to the Essentials of Transfusion Medicine
-
Aug 23, 2026, 16:35Thomas Dayspring: The Overlooked Pathway in Cholesterol Homeostasis
-
Aug 23, 2026, 16:28Evan Mapelu: The People Who Make Cancer Care Meaningful
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia